@article{c7ed28a4e8b14ab7bf65d8b8a3edd3c3,
title = "The Clinical Trials Portfolio for On-label and Off-label Studies of Eculizumab",
author = "Kim, \{Myung S.\} and Vinay Prasad",
note = "Funding Information: National Institutes of Health (NIH) policy requires that nonapplicable clinical trials (non-ACTs) funded by grants submitted to NIH from January 18, 2017, also submit results.2 Funding Information: Author Contributions: Dr Kim had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: Prasad. Acquisition, analysis, or interpretation of data: Kim. Drafting of the manuscript: Kim. Critical revision of the manuscript for important intellectual content: Prasad. Supervision: Prasad. Conflict of Interest Disclosures: Dr Prasad receives research funding from the Laura and John Arnold Foundation. He also reports receiving royalties from his book Ending Medical Reversal; that his work is funded by the Laura and John Arnold Foundation; and that he has received honoraria for Grand Rounds/ lectures from several universities, medical centers, and professional societies and payments for contributions to Medscape. Dr Prasad also hosts the podcast Plenary Session, which has Patreon backers. No other disclosures were reported. 1. Gulbis B, Eleftheriou A, Angastiniotis M, et al. Epidemiology of rare anaemias in Europe. Adv Exp Med Biol. 2010;686:375-396. doi:10.1007/978-90-481-9485-8\_22 2. Herper M. The world's most expensive drugs. https://www.forbes.com/2010/ 02/19/expensive-drugs-cost-business-healthcare-rare-diseases.html. Published 2010. Accessed June 25, 2019.",
year = "2020",
month = feb,
doi = "10.1001/jamainternmed.2019.4694",
language = "English (US)",
volume = "180",
pages = "315--317",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "2",
}